Inuvair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress inflammatory mediators, reduce swelling, and limit immune‑cell activity. This anti‑inflammatory action helps keep the airways less reactive and less prone to narrowing.

Formoterol fumarate selectively activates β2‑adrenergic receptors on airway smooth‑muscle cells, increasing cyclic AMP levels. The rise in cAMP leads to relaxation of the muscle, producing a long‑lasting bronchodilatory effect that helps keep the airways open for up to 12 hours.

The prescribed dose of Inuvair is individualized by the treating physician based on disease severity, patient response, and clinical guidelines. The prescriber determines the number of inhalations per day and the total daily dose, which may be adjusted over time.

Safety data for Inuvair in pregnancy and lactation are limited. The decision to use the product should be made by a healthcare professional after weighing potential benefits against possible risks to the fetus or infant. Women who are pregnant or nursing should discuss their treatment options with their doctor.

To order Inuvair, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inuvair contains beclometasone dipropionate and formoterol fumarate, a pairing that offers potent anti‑inflammatory activity together with a rapid‑onset, long‑duration bronchodilator. Compared with alternatives such as budesonide/formoterol or fluticasone/salmeterol, Inuvair provides a similar efficacy profile, but the specific corticosteroid potency and pharmacokinetic properties may differ, influencing dosing frequency and side‑effect risk.

Inuvair should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler upright, avoid exposing it to extreme temperatures, and replace the device after the indicated number of doses or when the dose counter reaches zero.

Inuvair is delivered via a metered‑dose inhaler. The patient should shake the inhaler, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the device. After each inhalation, the mouth should be rinsed with water to reduce the risk of oral thrush.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, pneumonia (particularly in COPD patients), cardiac arrhythmias or tachycardia, severe allergic reactions such as anaphylaxis, and significant hyperglycemia in diabetic patients. Any of these symptoms require immediate medical attention.

Inuvair is contraindicated in patients with known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It should also be avoided in individuals who have experienced a severe allergic reaction to other inhaled corticosteroid/LABA products. Patients with uncontrolled cardiovascular disease should use it only under close medical supervision.